Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học: " F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) | Cook et al. EJNMMI Research 2011 1 4 http www.ejnmmires.eom content 1 1 4 9 EJNMMI Research a SpringerOpen Journal PRELIMINARY RESEARCH Open Access 18F-fluoride PET changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride Alpharadin 1 21 2 3 1 Gary JR Cook Chris Parker Sue Chua Bernadette Johnson Anne-Kirsti Aksnes and Val J Lewington Abstract Background A qualitative assessment of conventional bone scintigraphy with 99mTc methylene diphosphonate is perceived as an insensitive method for monitoring the treatment response of bone metastases and we postulated that semi-quantitative 18F-fluoride positron emission tomography PET might serve as a suitable alternative biomarker of the treatment response. Methods Five patients with castrate-resistant prostate cancer and bone metastases with no known soft tissue disease received 100 kBq kg of radium-223 223Ra -chloride Alpharadin therapy at 0 and 6 weeks and had whole body 18F-fluoride PET scans at baseline 6 and 12 weeks with concurrent prostatic-specific antigen PSA and alkaline phosphatase ALP measurements. A qualitative comparison of the PET scans was performed blinded to the PSA and ALP results. A semi-quantitative comparison was made by measuring the maximum standardised uptake values SUVmax in five bone metastases in each patient. The means of the five SUVmax measurements in each subject were used as a quantitative measure of global metastatic activity at each time point. Results Three patients showed a PSA decline at 12 weeks -44 -31 -27 reduction whilst two patients showed PSA increases 10 17 . All five patients showed a reduction in ALP of greater than 25 . The qualitative assessment of the 18F-fluoride scans recorded a stable disease in each case. However the semi-quantitative assessment showed agreement with the PSA decline in three patients -52 -75 -49 and minimal change 12 -16 in two patients with increased PSA at 12 .